The company said the products have been formulated with VESIsorb for “optimized absorption, bioavailability, and rapid onset of action”
Heritage Cannabis Holdings Corp (CSE:CANN) (OTCQX:HERTF) (FRA:2UE) revealed on Thursday that this year, it would launch in the US, several new medical products, formulated with its patented VESIsorb drug delivery technology through its subsidiary Opticann.
The Toronto-based cannabis company said the products, to be introduced in a phased manner, would include ArthroCBD soft gel capsules, as well as topical cannabinoid applications created to address eczema, psoriasis, and local pain.
“We continue to innovate and expand our clinically proven cannabinoid product offerings as we launch our initial suite of products formulated with the VESIsorb drug delivery system technology,” said Umar Syed, President of the Medical Division at Heritage.
READ: Heritage Cannabis expands US supply and distribution agreement with Geocann for products utilizing VESIsorb technology
“With our products, we aim to reach the broader healthcare market that includes sophisticated consumers and healthcare professionals, who are seeking highly effective products that have substantial safety and efficacy data to support their utility for medical applications,” he added.
The company plans to launch its first product, ArthroCBD 25 mg CBD and 6 mg beta-caryophyllene (BCP) soft gel capsules by April 19. Heritage said the product has been formulated with VESIsorb for “optimized absorption, bioavailability, and rapid onset of action.”
In addition, Heritage said CBD topical applications formulated with VESIsorb for maximum skin penetration are in the “final stages of product development” with a launch planned in the summer on Opticann.com, as well as at leading retailers in the food, drug, and mass market.
“Opticann’s CBD/CBDA sublingual filmstrip, which is already planned for launch in Canada and Australia, will also be launched through the e-commerce effort later this year,” said the company.
In the run-up to the launch, Opticann is presenting its products and brands at the National Association of Chain Drug Stores (NACDS) annual meeting in late-April.
VESIsorb is an innovative drug delivery technology for dramatically improving the stability, absorption, and bioavailability of natural ingredients like cannabinoids, and is backed by a robust body of supporting scientific evidence spanning several decades.
Most recently, the peer-reviewed journal 'Molecules', published the results of a double-blind, cross-over study comparing the pharmacokinetic performance of a CBD extract formulated with VESIsorb to that of the same CBD extract formulated with industry-standard (MCT) oil.
Overall, the VESIsorb formulation showed statistically significant improvements for all measured parameters, including much higher total absorption (a 440% increase in maximum plasma CBD concentration, and a 285% increase in total CBD exposure over 8 hours AUC). In addition, the time to reach the peak concentration was 300% faster than the standard formulation (one hour for VESIsorb versus three hours for the standard to reach Tmax).
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive
